Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05158387




Registration number
NCT05158387
Ethics application status
Date submitted
2/12/2021
Date registered
15/12/2021
Date last updated
27/06/2024

Titles & IDs
Public title
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Scientific title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)
Secondary ID [1] 0 0
2021-003771-34
Secondary ID [2] 0 0
D9180C00004
Universal Trial Number (UTN)
Trial acronym
TITANIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease (COPD) 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tozorakimab
Treatment: Drugs - Tozorakimab
Treatment: Drugs - Placebo

Experimental: Tozorakimab Dose 1 - Dosing subcutaneously tozorakimab Dose 1 and placebo

Experimental: Tozorakimab Dose 2 - Dosing subcutaneously tozorakimab Dose 2

Placebo comparator: Placebo - Dosing subcutaneously with equivalent volume to tozorakimab


Treatment: Drugs: Tozorakimab
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

Treatment: Drugs: Tozorakimab
Administered subcutaneously tozorakimab Dose 2 through Week 52.

Treatment: Drugs: Placebo
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
Timepoint [1] 0 0
over 52 weeks
Secondary outcome [1] 0 0
Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
Timepoint [1] 0 0
over 52 weeks
Secondary outcome [2] 0 0
Time to first moderate to severe COPD exacerbation in former smokers.
Timepoint [2] 0 0
over 52 weeks
Secondary outcome [3] 0 0
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.
Timepoint [3] 0 0
Week 52, or over 52 weeks
Secondary outcome [4] 0 0
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in the overall population of current and former smokers.
Timepoint [4] 0 0
Week 52, or over 52 weeks
Secondary outcome [5] 0 0
Percentage of responders achieving MCID in E-RS:COPD total score in former smokers
Timepoint [5] 0 0
Week 52
Secondary outcome [6] 0 0
Percentage of responders achieving MCID in E-RS:COPD total score in the overall population of current and former smokers.
Timepoint [6] 0 0
Week 52
Secondary outcome [7] 0 0
Mean change from baseline in E-RS:COPD total score in former smokers.
Timepoint [7] 0 0
over 52 weeks
Secondary outcome [8] 0 0
Mean change from baseline in E-RS:COPD total score in the overall population of current and former smokers.
Timepoint [8] 0 0
over 52 weeks
Secondary outcome [9] 0 0
Percentage of responders achieving MCID in SGRQ total score in former smokers.
Timepoint [9] 0 0
Week 52
Secondary outcome [10] 0 0
Percentage of responders achieving MCID in SGRQ total score in the overall population of current and former smokers.
Timepoint [10] 0 0
Week 52
Secondary outcome [11] 0 0
Mean change from baseline in SGRQ total score from in former smokers.
Timepoint [11] 0 0
over 52 weeks
Secondary outcome [12] 0 0
Mean change from baseline in SGRQ total score from in the overall population of current and former smokers.
Timepoint [12] 0 0
over 52 weeks
Secondary outcome [13] 0 0
Time to first severe COPD exacerbation in former smokers.
Timepoint [13] 0 0
over 52 weeks
Secondary outcome [14] 0 0
Annualized rate of severe COPD exacerbations in former smokers.
Timepoint [14] 0 0
over 52 weeks
Secondary outcome [15] 0 0
Change from baseline in CAT total score.
Timepoint [15] 0 0
Week 52
Secondary outcome [16] 0 0
Percentage of participants with a decrease in CAT total score in former smokers.
Timepoint [16] 0 0
Week 52
Secondary outcome [17] 0 0
Proportion of participants having = 1 healthcare resource utilization type in former smokers.
Timepoint [17] 0 0
over 52 weeks
Secondary outcome [18] 0 0
Annualized rate of healthcare resource utilization in former smokers.
Timepoint [18] 0 0
over 52 weeks
Secondary outcome [19] 0 0
The change from baseline in mean number of puffs per day in rescue use in former smokers.
Timepoint [19] 0 0
over 52 weeks
Secondary outcome [20] 0 0
Trough serum concentrations of tozorakimab.
Timepoint [20] 0 0
over 52 weeks
Secondary outcome [21] 0 0
Presence of anti-drug antibodies.
Timepoint [21] 0 0
over 60 weeks

Eligibility
Key inclusion criteria
1. Participant must be = 40 years of age and capable of giving signed informed consent.
2. Documented diagnosis of COPD for at least one year prior to enrolment.
3. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.
4. Documented history of = 2 moderate or = 1 severe COPD exacerbations within 12 months prior to enrolment.
5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
6. Smoking history of = 10 pack-years.
7. CAT total score =10, with each of the phlegm (sputum) and cough items with a score = 2
Minimum age
40 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Clinically important pulmonary disease other than COPD.
2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.
3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.
6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
8. Significant COVID-19 illness within the 6 months prior to enrolment.
9. Unstable cardiovascular disorder.
10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.
12. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C)
13. Evidence of active liver disease, including jaundice during screening.
14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
15. Participants who have evidence of active TB.
16. Participants that have previously received tozorakimab.
17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/08/2025
Actual
Sample size
Target
1060
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Adelaide
Recruitment hospital [2] 0 0
Research Site - Campbelltown
Recruitment hospital [3] 0 0
Research Site - Frankstown
Recruitment hospital [4] 0 0
Research Site - Macquarie University
Recruitment hospital [5] 0 0
Research Site - Melbourne
Recruitment hospital [6] 0 0
Research Site - Nedlands
Recruitment hospital [7] 0 0
Research Site - Southport
Recruitment hospital [8] 0 0
Research Site - Spearwood
Recruitment hospital [9] 0 0
Research Site - Wollongong
Recruitment hospital [10] 0 0
Research Site - Woodville South
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
2560 - Campbelltown
Recruitment postcode(s) [3] 0 0
3199 - Frankstown
Recruitment postcode(s) [4] 0 0
2109 - Macquarie University
Recruitment postcode(s) [5] 0 0
3000 - Melbourne
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment postcode(s) [7] 0 0
4215 - Southport
Recruitment postcode(s) [8] 0 0
6163 - Spearwood
Recruitment postcode(s) [9] 0 0
2500 - Wollongong
Recruitment postcode(s) [10] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Delaware
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Brazil
State/province [24] 0 0
Blumenau
Country [25] 0 0
Brazil
State/province [25] 0 0
Botucatu
Country [26] 0 0
Brazil
State/province [26] 0 0
Brasilia
Country [27] 0 0
Brazil
State/province [27] 0 0
Curitiba
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio de Janeiro
Country [30] 0 0
Brazil
State/province [30] 0 0
Sao Bernardo do Campo
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
São Paulo
Country [33] 0 0
Chile
State/province [33] 0 0
Curico
Country [34] 0 0
Chile
State/province [34] 0 0
Santiago
Country [35] 0 0
Chile
State/province [35] 0 0
Talca
Country [36] 0 0
China
State/province [36] 0 0
Anhui
Country [37] 0 0
China
State/province [37] 0 0
Baotou
Country [38] 0 0
China
State/province [38] 0 0
Beijing
Country [39] 0 0
China
State/province [39] 0 0
Changchun
Country [40] 0 0
China
State/province [40] 0 0
Changde
Country [41] 0 0
China
State/province [41] 0 0
Changsha
Country [42] 0 0
China
State/province [42] 0 0
Chengdu
Country [43] 0 0
China
State/province [43] 0 0
Chongqing
Country [44] 0 0
China
State/province [44] 0 0
Guangzhou
Country [45] 0 0
China
State/province [45] 0 0
Haikou
Country [46] 0 0
China
State/province [46] 0 0
Hangzhou
Country [47] 0 0
China
State/province [47] 0 0
Hefei
Country [48] 0 0
China
State/province [48] 0 0
Hohhot
Country [49] 0 0
China
State/province [49] 0 0
Kunming
Country [50] 0 0
China
State/province [50] 0 0
Linhai
Country [51] 0 0
China
State/province [51] 0 0
Nanchang
Country [52] 0 0
China
State/province [52] 0 0
Nanjing
Country [53] 0 0
China
State/province [53] 0 0
Ningbo
Country [54] 0 0
China
State/province [54] 0 0
Shanghai
Country [55] 0 0
China
State/province [55] 0 0
Shengyang
Country [56] 0 0
China
State/province [56] 0 0
Shenyang
Country [57] 0 0
China
State/province [57] 0 0
Shenzhen
Country [58] 0 0
China
State/province [58] 0 0
Shijiazhuang
Country [59] 0 0
China
State/province [59] 0 0
Suzhou
Country [60] 0 0
China
State/province [60] 0 0
Taiyuan
Country [61] 0 0
China
State/province [61] 0 0
Tianjin
Country [62] 0 0
China
State/province [62] 0 0
Urumqi
Country [63] 0 0
China
State/province [63] 0 0
Wuhan
Country [64] 0 0
China
State/province [64] 0 0
Wuxi
Country [65] 0 0
China
State/province [65] 0 0
Xiamen
Country [66] 0 0
China
State/province [66] 0 0
Xuzhou
Country [67] 0 0
China
State/province [67] 0 0
Yangzhou
Country [68] 0 0
China
State/province [68] 0 0
Yinchuan
Country [69] 0 0
China
State/province [69] 0 0
Zhanjiang
Country [70] 0 0
China
State/province [70] 0 0
Zunyi
Country [71] 0 0
Colombia
State/province [71] 0 0
Barranquilla
Country [72] 0 0
Colombia
State/province [72] 0 0
Bogotá
Country [73] 0 0
Colombia
State/province [73] 0 0
Ibague
Country [74] 0 0
Colombia
State/province [74] 0 0
Medellin
Country [75] 0 0
Colombia
State/province [75] 0 0
Rionegro
Country [76] 0 0
Colombia
State/province [76] 0 0
Zipaquira
Country [77] 0 0
France
State/province [77] 0 0
Brest Cedex 2
Country [78] 0 0
France
State/province [78] 0 0
Dijon Cedex
Country [79] 0 0
France
State/province [79] 0 0
Grenoble cedex 9
Country [80] 0 0
France
State/province [80] 0 0
Limoges
Country [81] 0 0
France
State/province [81] 0 0
Lyon Cedex
Country [82] 0 0
France
State/province [82] 0 0
Marseille
Country [83] 0 0
France
State/province [83] 0 0
Montivilliers
Country [84] 0 0
France
State/province [84] 0 0
Montpellier
Country [85] 0 0
France
State/province [85] 0 0
Pessac
Country [86] 0 0
France
State/province [86] 0 0
Saint-Herblain
Country [87] 0 0
France
State/province [87] 0 0
Suresnes Cedex
Country [88] 0 0
France
State/province [88] 0 0
Toulouse
Country [89] 0 0
Germany
State/province [89] 0 0
Bamberg
Country [90] 0 0
Germany
State/province [90] 0 0
Berlin
Country [91] 0 0
Germany
State/province [91] 0 0
Darmstadt
Country [92] 0 0
Germany
State/province [92] 0 0
Frankfurt
Country [93] 0 0
Germany
State/province [93] 0 0
Großhansdorf
Country [94] 0 0
Germany
State/province [94] 0 0
Halle
Country [95] 0 0
Germany
State/province [95] 0 0
Köln
Country [96] 0 0
Germany
State/province [96] 0 0
Marburg
Country [97] 0 0
Germany
State/province [97] 0 0
München-Pasing
Country [98] 0 0
Germany
State/province [98] 0 0
München
Country [99] 0 0
Germany
State/province [99] 0 0
Peine
Country [100] 0 0
Greece
State/province [100] 0 0
Alexandroupolis
Country [101] 0 0
Greece
State/province [101] 0 0
Athens
Country [102] 0 0
Greece
State/province [102] 0 0
Exohi Thessaloniki
Country [103] 0 0
Greece
State/province [103] 0 0
Ioannina
Country [104] 0 0
Greece
State/province [104] 0 0
Patras
Country [105] 0 0
Greece
State/province [105] 0 0
Thessaloniki
Country [106] 0 0
Israel
State/province [106] 0 0
Ashkelon
Country [107] 0 0
Israel
State/province [107] 0 0
Beer Sheva
Country [108] 0 0
Israel
State/province [108] 0 0
Jerusalem
Country [109] 0 0
Israel
State/province [109] 0 0
Kfar-Saba
Country [110] 0 0
Israel
State/province [110] 0 0
Rehovot
Country [111] 0 0
Israel
State/province [111] 0 0
Tel Aviv
Country [112] 0 0
Italy
State/province [112] 0 0
Bari
Country [113] 0 0
Italy
State/province [113] 0 0
Macerata
Country [114] 0 0
Italy
State/province [114] 0 0
Massa
Country [115] 0 0
Italy
State/province [115] 0 0
Messina
Country [116] 0 0
Italy
State/province [116] 0 0
Milano
Country [117] 0 0
Italy
State/province [117] 0 0
Napoli
Country [118] 0 0
Italy
State/province [118] 0 0
Roma
Country [119] 0 0
Italy
State/province [119] 0 0
Salerno
Country [120] 0 0
Italy
State/province [120] 0 0
San Donà di Piave
Country [121] 0 0
Italy
State/province [121] 0 0
Sassari
Country [122] 0 0
Italy
State/province [122] 0 0
Statte
Country [123] 0 0
Italy
State/province [123] 0 0
Telese Terme
Country [124] 0 0
Italy
State/province [124] 0 0
Tradate
Country [125] 0 0
Italy
State/province [125] 0 0
Vercelli
Country [126] 0 0
Italy
State/province [126] 0 0
Verona
Country [127] 0 0
Peru
State/province [127] 0 0
Lima
Country [128] 0 0
Peru
State/province [128] 0 0
Piura
Country [129] 0 0
Philippines
State/province [129] 0 0
Baguio
Country [130] 0 0
Philippines
State/province [130] 0 0
Cebu City
Country [131] 0 0
Philippines
State/province [131] 0 0
Iloilo City
Country [132] 0 0
Philippines
State/province [132] 0 0
Manila
Country [133] 0 0
Poland
State/province [133] 0 0
Bialystok
Country [134] 0 0
Poland
State/province [134] 0 0
Bychawa
Country [135] 0 0
Poland
State/province [135] 0 0
Bydgoszcz
Country [136] 0 0
Poland
State/province [136] 0 0
Gdansk
Country [137] 0 0
Poland
State/province [137] 0 0
Grodzisk Mazowiecki
Country [138] 0 0
Poland
State/province [138] 0 0
Grudziadz
Country [139] 0 0
Poland
State/province [139] 0 0
Katowice
Country [140] 0 0
Poland
State/province [140] 0 0
Krakow
Country [141] 0 0
Poland
State/province [141] 0 0
Kraków
Country [142] 0 0
Poland
State/province [142] 0 0
Lublin
Country [143] 0 0
Poland
State/province [143] 0 0
Nowa Sól
Country [144] 0 0
Poland
State/province [144] 0 0
Ostrowiec Swietokrzyski
Country [145] 0 0
Poland
State/province [145] 0 0
Ostróda
Country [146] 0 0
Poland
State/province [146] 0 0
Poznan
Country [147] 0 0
Poland
State/province [147] 0 0
Rzeszów
Country [148] 0 0
Poland
State/province [148] 0 0
Skierniewice
Country [149] 0 0
Poland
State/province [149] 0 0
Sosnowiec
Country [150] 0 0
Poland
State/province [150] 0 0
Warszawa
Country [151] 0 0
Poland
State/province [151] 0 0
Wolomin
Country [152] 0 0
Poland
State/province [152] 0 0
Wroclaw
Country [153] 0 0
Puerto Rico
State/province [153] 0 0
Caguas
Country [154] 0 0
Puerto Rico
State/province [154] 0 0
Ponce
Country [155] 0 0
Romania
State/province [155] 0 0
Brasov
Country [156] 0 0
Romania
State/province [156] 0 0
Bucharest
Country [157] 0 0
Romania
State/province [157] 0 0
Bucuresti
Country [158] 0 0
Romania
State/province [158] 0 0
Cluj-Napoca
Country [159] 0 0
Romania
State/province [159] 0 0
Constanta
Country [160] 0 0
Romania
State/province [160] 0 0
Iasi
Country [161] 0 0
Romania
State/province [161] 0 0
Timisoara
Country [162] 0 0
Russian Federation
State/province [162] 0 0
Chelyabinsk
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Izhevsk
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Moscow
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Novosibirsk
Country [166] 0 0
Russian Federation
State/province [166] 0 0
Penza
Country [167] 0 0
Russian Federation
State/province [167] 0 0
Perm
Country [168] 0 0
Russian Federation
State/province [168] 0 0
Saint Petersburg
Country [169] 0 0
Russian Federation
State/province [169] 0 0
Saratov
Country [170] 0 0
Russian Federation
State/province [170] 0 0
Tomsk
Country [171] 0 0
Russian Federation
State/province [171] 0 0
Ulyanovsk
Country [172] 0 0
Taiwan
State/province [172] 0 0
Hsinchu
Country [173] 0 0
Taiwan
State/province [173] 0 0
Kaohsiung
Country [174] 0 0
Taiwan
State/province [174] 0 0
Taichung
Country [175] 0 0
Taiwan
State/province [175] 0 0
Taipei City
Country [176] 0 0
Taiwan
State/province [176] 0 0
Taipei
Country [177] 0 0
Taiwan
State/province [177] 0 0
Taoyuan
Country [178] 0 0
Taiwan
State/province [178] 0 0
Yunlin
Country [179] 0 0
Thailand
State/province [179] 0 0
Bang Kra So
Country [180] 0 0
Thailand
State/province [180] 0 0
Bangkok
Country [181] 0 0
Thailand
State/province [181] 0 0
Hat Yai
Country [182] 0 0
Thailand
State/province [182] 0 0
Khon Kaen
Country [183] 0 0
Thailand
State/province [183] 0 0
Muang,
Country [184] 0 0
Thailand
State/province [184] 0 0
Muang
Country [185] 0 0
Thailand
State/province [185] 0 0
Mueang
Country [186] 0 0
Thailand
State/province [186] 0 0
Nakhon Ratchasima
Country [187] 0 0
United Kingdom
State/province [187] 0 0
Blackpool
Country [188] 0 0
United Kingdom
State/province [188] 0 0
Bradford
Country [189] 0 0
United Kingdom
State/province [189] 0 0
Corby
Country [190] 0 0
United Kingdom
State/province [190] 0 0
Enfield
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Glasgow
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Hampshire
Country [193] 0 0
United Kingdom
State/province [193] 0 0
High Wycombe
Country [194] 0 0
United Kingdom
State/province [194] 0 0
London
Country [195] 0 0
United Kingdom
State/province [195] 0 0
Northwood
Country [196] 0 0
United Kingdom
State/province [196] 0 0
Preston
Country [197] 0 0
United Kingdom
State/province [197] 0 0
Shipley
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Wokingham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of = 2 moderate or = 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.
Trial website
https://clinicaltrials.gov/study/NCT05158387
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05158387